Beyond the PGx Report: Building PGx Services That Support Real-World Prescribing

Pharmacogenomics (PGx) is a foundational component of precision medicine, yet many laboratories and health systems continue to face challenges translating PGx evidence into routine clinical workflows. As PGx expands beyond niche use cases, there is growing demand for scalable approaches that integrate testing, reporting, and clinical decision support (CDS) across diverse care settings while supporting both clinical impact and commercial sustainability.

This webinar will illustrate how PGx can be operationalized in real-world clinical practice through a series of case vignettes spanning oncology, cardiology, and long-term care. Through these cases, speakers will demonstrate how laboratories and health systems can incorporate PGx into existing workflows, align PGx with guideline-driven care, and leverage CDS to support precision prescribing throughout a patient’s clinical journey.

Topics will include the use of DPYD testing as an entry point for PGx integration within precision oncology workflows, the role of pre-emptive PGx testing when results become clinically actionable at the point of care, and the clinical and commercial value of PGx in long-term care settings characterized by polypharmacy and complex medication management. Attendees will gain practical insights into how PGx can be embedded alongside somatic testing, medication review, and multifactorial decision-making to improve patient safety, reduce adverse drug events, and support scalable PGx adoption across care environments.

After attending this webinar, participants will be able to:

• Describe how pharmacogenomic testing can be integrated into routine clinical workflows across oncology, cardiology, and long-term care settings.
   
• Evaluate the role of PGx reporting and clinical decision support in guiding precision prescribing when multiple clinical factors, including drug–gene and drug–drug interactions, must be considered.
   
• Identify implementation strategies that enable laboratories and health systems to scale PGx programs while supporting both clinical outcomes and commercial viability.